Bioregenx annual operating margin
2021
2022
2023
2024
2025
Bioregenx's operating margin was −67.08% for fiscal 2025.
View full Bioregenx company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −67.08% | +905.67 pp |
| 2024 | 2024-12-31 | −972.75% | −872.82 pp |
| 2023 | 2023-12-31 | −99.92% | +85.82 pp |
| 2022 | 2022-12-31 | −185.74% | −102.60 pp |
| 2021 | 2021-12-31 | −83.15% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q1 2026 | 2026-03-31 | −11.68% | +25.71 pp |
| Q4 2025 | 2025-12-31 | −242.62% | +3735.06 pp |
| Q3 2025 | 2025-09-30 | −1.67% | +53.25 pp |
| Q2 2025 | 2025-06-30 | −24.05% | +117.60 pp |
| Q1 2025 | 2025-03-31 | −37.39% | +522.97 pp |
| Q4 2024 | 2024-12-31 | −3,977.69% | −3946.49 pp |
| Q3 2024 | 2024-09-30 | −54.91% | +255.77 pp |
| Q2 2024 | 2024-06-30 | −141.66% | −78.57 pp |
| Q1 2024 | 2024-03-31 | −560.36% | −543.24 pp |
| Q4 2023 | 2023-12-31 | −31.20% | +30.89 pp |
| Q3 2023 | 2023-09-30 | −310.69% | −291.27 pp |
| Q2 2023 | 2023-06-30 | −63.09% | +170.21 pp |
| Q1 2023 | 2023-03-31 | −17.12% | +467.29 pp |
| Q4 2022 | 2022-12-31 | −62.09% | — |
| Q3 2022 | 2022-09-30 | −19.42% | — |
| Q2 2022 | 2022-06-30 | −233.29% | — |
| Q1 2022 | 2022-03-31 | −484.41% | — |
Across the available reported history, Bioregenx's operating margin increased from −972.75% to −67.08%, a change of +905.67 percentage points. The latest reported quarter, Q1 2026, shows −11.68%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Bioregenx filings at SEC.gov ↗